Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects

被引:36
|
作者
Al-Hamodi, Zaid [1 ]
Ismail, Ikram S. [2 ]
Saif-Ali, Riyadh [1 ,3 ]
Ahmed, Khaled A. [4 ]
Muniandy, Sekaran [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Dept Med, Kuala Lumpur 50603, Malaysia
[3] Sanaa Univ, Fac Med, Dept Biochem, Sanaa, Yemen
[4] Ibb Univ, Fac Dent, Ibb, Yemen
来源
关键词
CORONARY-HEART-DISEASE; INSULIN-RESISTANCE SYNDROME; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; RISK-FACTORS; FIBRINOLYTIC SYSTEM; PREDICTIVE-VALUE; PLASMA; OBESITY; INFLAMMATION;
D O I
10.1186/1475-2840-10-23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1 and tPA activities and antigens in Malaysian T2D and normal subjects. Methods: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 nondiabetic MetS subjects. Results: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 x 10(-19)) and non-diabetic subjects with MetS (P = 3.0 x 10(-15)), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 x 10(-24)), T2D without MetS (P = 1.3 x 10(-13)) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects were related to insulin resistance (P = 2.2 x 10(-4); 0.007). Additionally, the PAI-1 activity was associated with an increased waist circumference (P = 2.2 x 10(-4)) and decreased HDL-c (P = 0.005), whereas the tPA activity was associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen (R-2 = 0.695, P = 1.1 x 10(-36)) in diabetic subjects. The tPA activity negatively correlated with its antigen (R-2 = -0.444, P = 7.7 x 10(-13)) in normal subjects and with the PAI-1 activity and antigen (R-2 = -0.319, P = 9.9 x 10(-12); R2 = -0.228, P = 3.4 x 10(-6)) in diabetic subjects. Conclusions: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in Malaysian subjects.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
    Yu Zuo
    Mark Warnock
    Alyssa Harbaugh
    Srilakshmi Yalavarthi
    Kelsey Gockman
    Melanie Zuo
    Jacqueline A. Madison
    Jason S. Knight
    Yogendra Kanthi
    Daniel A. Lawrence
    Scientific Reports, 11
  • [42] THE MECHANISM OF THE REACTION BETWEEN HUMAN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND TISSUE PLASMINOGEN-ACTIVATOR
    LINDAHL, TL
    OHLSSON, PI
    WIMAN, B
    BIOCHEMICAL JOURNAL, 1990, 265 (01) : 109 - 113
  • [43] Prognostic value of plasminogen activator inhibitor-1 and tissue plasminogen activator in the evaluation of patients with chest pain
    Glynn, T.
    Friedman, S. A.
    Link, C. A.
    Hughes, M.
    Felton, B.
    Ginsberg, D. S.
    Day, D. E.
    ANNALS OF EMERGENCY MEDICINE, 2007, 50 (03) : S78 - S78
  • [44] Polymerization of plasminogen activator inhibitor-1
    Zhou, A
    Faint, R
    Charlton, P
    Dafforn, TR
    Carrell, RW
    Lomas, DA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) : 9115 - 9122
  • [45] Plasminogen activator inhibitor-1 and the kidney
    Eddy, AA
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (02) : F209 - F220
  • [46] Plasminogen Activator Inhibitor-1 in Aging
    Yamamoto, Koji
    Takeshita, Kyosuke
    Saito, Hidehiko
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (06): : 652 - 659
  • [47] PLASMINOGEN-ACTIVATOR INHIBITOR-1
    LOSKUTOFF, DJ
    MIMURO, J
    HEKMAN, C
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 534 - 534
  • [48] Plasminogen activator inhibitor-1 and Restenosis
    Garg, Nadish
    Fay, William P.
    CURRENT DRUG TARGETS, 2007, 8 (09) : 1003 - 1006
  • [49] Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms inn patients with chronic periodontitis
    Gurkan, Ali
    Emingil, Gulnur
    Saygan, Buket Han
    Cinarcik, Serhat
    Atilla, Gul
    Kose, Timur
    Berdeli, Afig
    JOURNAL OF PERIODONTOLOGY, 2007, 78 (07) : 1256 - 1263
  • [50] PLASMINOGEN-ACTIVATOR INHIBITOR-1(PAI-1) AND TISSUE-PLASMINOGEN ACTIVATOR PLASMINOGEN-ACTIVATOR INHIBITOR-1(TPA-PAI-1) IN IDDM - PROFILE BY COMPLICATIONS
    SUMINSKI, R
    DASILVA, S
    SMITH, M
    ERBEY, J
    DIABETES, 1994, 43 : A197 - A197